Neurocrine price target raised to $140 from $116 at Mizuho

Mizuho analyst Uy Ear raised the firm’s price target on Neurocrine to $140 from $116 and keeps a Neutral rating on the shares post the Q4 report. The first-time 2024 Ingrezza sales guidance and higher than expected spending guidance disappointed, the analyst tells investors in a research note. The firm says the 2024 Ingrezza sales guidance could be conservative as it is based on current patient retention and new patient gain.